Last reviewed · How we verify
Initial remifentanil effect-site concentration
Initial remifentanil effect-site concentration is a Opioid agonist Small molecule drug developed by Tri-Service General Hospital. It is currently FDA-approved for Intraoperative analgesia and sedation during general anesthesia, Postoperative analgesia in monitored anesthesia care settings.
Remifentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce rapid analgesia and sedation.
Remifentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intraoperative analgesia and sedation during general anesthesia, Postoperative analgesia in monitored anesthesia care settings.
At a glance
| Generic name | Initial remifentanil effect-site concentration |
|---|---|
| Sponsor | Tri-Service General Hospital |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Analgesia |
| Phase | FDA-approved |
Mechanism of action
Remifentanil activates mu-opioid receptors, which inhibit pain signal transmission and promote sedation through effects on the brainstem and spinal cord. It is characterized by rapid onset and offset due to its ester structure, which allows quick metabolism by non-specific plasma and tissue esterases. The 'effect-site concentration' refers to the measured or modeled concentration at the site of drug action (brain), used to guide dosing in anesthesia.
Approved indications
- Intraoperative analgesia and sedation during general anesthesia
- Postoperative analgesia in monitored anesthesia care settings
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Muscle rigidity
- Nausea and vomiting
Key clinical trials
- The Effects of Three Different Anesthetic Methods on Postoperative Agitation (NA)
- Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery (NA)
- Enhanced Recovery After Urologic Surgery (NA)
- Optimal Dosage of Remifentanil for Vertebroplasty (PHASE4)
- Pharmacodynamic Interaction of REMI and DMED (PHASE4)
- NOL Index to Compare the Intraoperative Analgesic Effect of Propofol Versus Sevoflurane (PHASE4)
- Evaluation of Bispectral Index (BIS™) and Levels of Sedation With Common Inhalational Anesthetics in Healthy Volunteers (OLIVER) (NA)
- Evaluation of the Analgesia Nociception Index With Varying Remifentanil Concentrations Under Sevoflurane (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Initial remifentanil effect-site concentration CI brief — competitive landscape report
- Initial remifentanil effect-site concentration updates RSS · CI watch RSS
- Tri-Service General Hospital portfolio CI
Frequently asked questions about Initial remifentanil effect-site concentration
What is Initial remifentanil effect-site concentration?
How does Initial remifentanil effect-site concentration work?
What is Initial remifentanil effect-site concentration used for?
Who makes Initial remifentanil effect-site concentration?
What drug class is Initial remifentanil effect-site concentration in?
What development phase is Initial remifentanil effect-site concentration in?
What are the side effects of Initial remifentanil effect-site concentration?
What does Initial remifentanil effect-site concentration target?
Related
- Drug class: All Opioid agonist drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Tri-Service General Hospital — full pipeline
- Therapeutic area: All drugs in Anesthesia and Analgesia
- Indication: Drugs for Intraoperative analgesia and sedation during general anesthesia
- Indication: Drugs for Postoperative analgesia in monitored anesthesia care settings
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing